Continuous treatment with secukinumab 300 mg demonstrates sustained efficacy in clearing skin, and improving patient-reported outcomes in moderate-to-severe plaque-psoriasis: Two-year results from the CLEAR-study Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Spelman, L
  • Blauvelt, A
  • Puig, L
  • Reich, K
  • Tsai, T
  • Tyring, S
  • Kingo, K
  • Ziv, M
  • Pinter, A
  • Vender, Ronald
  • Lacombe, A
  • Xia, S
  • Bhosekar, V
  • Gilloteau, I
  • Guana, A
  • Thaci, D

publication date

  • May 1, 2018